4BASEBIO PLC (4BB) — Investor Presentation

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the 4BASEBIO PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Amy Walker, CEO. Thank you very much. So I'd like to start off today with 4BASEBIO's mission statement, and that's really through our enzymatically produced DNA, we enable clinical and commercial biomanufacturing for advanced therapeutics, empowering safer, faster, more cost effective treatments to improve outcomes for patients worldwide. I'd also like to take the opportunity to introduce the new leadership team here at 4BASEBIO. So so people might remember me. My name is Amy Walker. I'm the chief executive officer, and I was appoint appointed as CEO, in February of this year, formerly serving as as chief operating officer. Next to me on the slide is Christine Willison. Chrissy will join me for this call today, and Chrissy serves as our chief commercial officer. She has a wealth of experience over a range of different CDMO businesses, including Trilink and Thermo Fisher as well. As we move across, we have Scott Lorimer, who was appointed as chief operating officer earlier this year. And like Chrissy, he has a wealth of experience in the industry leading global operations for a number of companies, including Catalent, Sanofi Genzyme, and Patheon as...